Skip to main content

Table 4 Clinical outcome measures & the IPAQ

From: The effect of combined Action Observation Therapy with eccentric exercises in the treatment of mid-portion Achilles-tendinopathy: a feasibility pilot randomised controlled trial

Outcome

Control group

 

Intervention group

  
 

% exceeding MCID

 

% exceeding MCID

ANCOVA

VISA-A

 Baseline

68.2 (17.2)

 

64.2 (13.6)

  

 Week 6

75.8 (13.0)

 

82.3 (10.3)

  

 Week 12

84.7 (11.5)

 

86.4 (18.2)

  

 Mean difference at 6 weeks (95% CI)

7.6 (0.28 to 14.9)

33

18.1 (10.2 to 26.0)

75

p = 0.037 η2 = 0.192

 Mean difference at 12 weeks (95% CI)

16.5 (8.5 to 24.5)

58

22.3 (12.5 to 32.0)

75

p = 0.447

η2 = 0.028

Left heel-raises (n)

 Baseline

20.8 (8.7)

 

25.9 (11.9)

  

 Week 6

25.0 (8.8)

 

30.2 (15.5)

  

 Week 12

28.8 (11.6)

 

38.2 (18.1)

  

 Mean difference at 6 weeks (95% CI)

4.2 (0.6 to 7.7)

 

4.3 (− 1.0 to 9.5)

  

 Mean difference at 12 weeks (95% CI)

7.9 (2.9 to 12.9)

 

12.2 (3.4 to 21)

  

Right heel-raises (n)

 Baseline

22.6 (8.2)

 

25.3 (10.6)

  

 Week 6

24.8 (9.5)

 

28.7 (10.9)

  

 Week 12

28.7 (10.6)

 

33.9 (14.6)

  

 Mean difference at 6 weeks (95% CI)

2.2 (− 1.6 to 6.0)

 

3.42 (− 0.9 to 7.7)

  

 Mean difference at 12 weeks (95% CI)

6.1 (0.5 to 11.6)

 

8.6 (3 to 14.4)

  

Left Hop Test (NPRS)

 Baseline

4.8 (2)

 

4.1 (1.9)

  

 Week 6

2.29 (2.43)

 

2.7 (2.2)

  

 Week 12

1.14 (1.86)

 

0.8 (1.6)

  

 Mean difference at 6 weeks (95% CI)

− 2.6 (− 4.5 to − 0.7)

 

− 1.1 (− 3.4 to 1.2)

  

 Mean difference at 12 weeks (95% CI)

− 3.4 (− 5.9 to − 1.0)

 

− 3.3 (− 5.9 to − 0.8)

  

Right hop test (NPRS)

 Baseline

3.3 (1.5)

 

5.1 (1.7)

  

 Week 6

1.6 (2.3)

 

1.7 (3.6)

  

 Week 12

0.5 (1.0)

 

1.7 (2.9)

  

 Mean difference at 6 weeks (95% CI)

− 0.8 (− 1.8 to .24)

 

− 3.3 (− 6.5 to − 0.2)

  

 Mean difference at 12 weeks (95% CI)

− 2.3 (− 5.5 – 1.0)

 

− 3.8 (− 6.7 to − 1.0)

  

NPRS

 Baseline

5.6 (1.9)

 

5.3 (2.3)

  

 Week 6

4.4 (2.1)

 

3.3 (2.4)

  

 Week 12

1.8 (1.29)

 

1.3 (2.1)

  

 Mean difference at 6 weeks (95% CI)

− 1.2 (− 2.4 to 0.1)

58

− 1.9 (− 3.7 to − 0.2)

50

 

 Mean difference at 12 weeks (95% CI)

− 3.8 (− 5.2 to − 2.5)

75

− 4 (− 5.7 to − 2.3)

83

 

LEFS

 Baseline

78.9 (15.2)

 

77.0 (16.6)

  

 Week 6

84.5 (12.2)

 

88.7 (9.6)

  

 Week 12

94.5 (7.41)

 

92.9 (8.5)

  

 Mean difference at 6 weeks (95% CI)

5.6 (1.5 to 9.8)

17

11.7 (4.1 to 19.3)

42

 

 Mean difference at 12 weeks (95% CI)

15.6 (8.7 to 22.6)

66

16 (8.3 to 23.6)

58

 

PSEQ

 Baseline

52.8 (7.4)

 

52.75 (7.0)

  

 Week 6

55.6 (6.1)

 

54.7 (4.7)

  

 Week 12

57.3 (4.3)

 

56.7 (4.6)

  

 Mean difference at 6 weeks (95% CI)

2.8 (0.1 to 5.6)

0

2.8 (− 1.1 to 6.6)

25

 

 Mean difference at 12 weeks (95% CI)

4.6 (1.3 to 7.9)

17

4.8 (1.5 to 8.0)

8

 

EUROQOL-5D VAS

 Baseline (95% CI)

83.9 (78.9 to 88.8)

 

80.0 (72.3 to 85.7)

  

 Week 6 (95% 5CI)

85.0 (80.1 to 89.9)

 

82.5 (73.9 to 91.1)

  

 WEEK 12 (95%CI)

87.0 (82.7 to 91.5)

 

82.4 (74.2 to 90.6)

  

PGIC

     

 Very much improved week 6/week 12(N)

1/6

 

4/8

  

 Much improved

week 6/week 12 (N)

6/5

 

4/1

  

 Minimally improved

week 6 /week 12 (N)

5/1

 

2/2

  

 No change

week 6/week 12 (N)

0/0

 

1/0

  

 Minimally worse

week 6/week 12 (N)

0/0

 

1/1

  

Satisfaction Q

 Excellent week 6/week 12 (N)

5/7

 

8/9

  

 Good week 6/week 12 (N)

4/3

 

1/1

  

 Moderate week 6/week 12 (N)

3/2

 

3/1

  

 POOR week 6/week 12 (N)

0/0

 

0/1

  

IPAQ

 Week 6 high/moderate/low

6/6/0

 

3/8/1

  

 week 12 high/moderate/low

8/3/1

 

3/8/1

  
  

N exceeding threshold

 

N exceeding threshold

PCS

 Baseline

14.7 (14.0)

3

15.6 (8.3)

1

 Week 6

8.4 (9.1)

1

6.6 (3.8)

0

 Week 12

2.9 (2.2)

0

3.7 (2.8)

0

 Mean difference at 6 weeks (95% CI)

− 6.3 (− 12.1 to − 0.4)

 

− 9.0 (− 14.4 to − 3.7)

 

 Mean difference at 12 weeks (95% CI)

− 11.8 (− 20.9 to − 2.6)

 

− 11.9 (− 17.8 to − 6.0)

 

TSK

 Baseline

34.6 (7.6)

 

38.4 (6.1)

 

 Week 6

33.3 (4.5)

2

34.0 (6.3)

4

Week 12

28.5 (5.2)

1

30.8 (6.2)

3

 Mean difference at 6 weeks (95% CI)

− 1.3 (− 4.4 to 1.9)

 

− 4.4 (− 6.2 to − 2.7)

 

 Mean difference at 12 weeks (95% CI)

− 6.1 (− 9.9 to − 2.3)

 

− 7.67 (− 11.3 to − 4.0)

 
  1. Results are presented as mean (std dev), mean difference (95% CI) and proportion exceeding MCID, η2 = partial eta squared is provided for the primary clinical outcome measure.
  2. N number, LEFS Lower Extremity Functional Scale, PSEQ Participant Self-Efficacy Questionnaire, PGIC Participant Global Impression of Change, Q Questionniare, IPAQ International Physical Activity Questionnaire, PCS Pain Catastrophising Scale, TSK Tampa Scale Kinesiophobia